Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIVI-TRUST: Ocriplasmin for Focal Vitreomacular Adhesion
NCT00781859Phase 3Completed
- Sponsor
- Oxurion
- Start
- Dec 2008
- Primary completion
- Mar 2010
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vitreomacular adhesion (VMA) comparing 125µg Ocriplasmin with Placebo (2 arms). Primary endpoint: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at 28 days. Started Dec 2008; status: completed.
02
Drugs
ocriplasmin
03
Conditions
vitreomacular adhesion (VMA)
Beyond the preview
Go deeper on NCT00781859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781859.